Chronic CRP-exposure inhibits VEGF-induced endothelial cell migration

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 2, 2010, Pages 203-212

  Schneeweis, Christopher ^a   Gräfe, Michael ^a   Bungenstock, Anne ^a   Spencer Hänsch, Chantel ^a   Fleck, Eckart ^a   Goetze, Stephan ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

Akt; C reactive protein; Endothelial cell; eNOS; Migration; PTEN

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOSPECIFIC ANTIBODY; PROTEIN KINASE B; VASCULOTROPIN;

ARTICLE; CELL ASSAY; CELL MIGRATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UMBILICAL VEIN; WESTERN BLOTTING;

EID: 77649214435     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.3004     Document Type: Article

References (51)

1. Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126
2. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation, 2002; 105: 1135-1143
3. Fan J, Watanabe T: Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb, 2003; 10: 63-71
4. Ferri C, Croce G, Cofini V, De Berardinis G, Grassi D, Casale R, Properzi G, Desideri G: C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. Curr Pharm Des, 2007; 13: 1631-1645
5. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med, 2004; 350: 1387-1397
6. Ridker PM, Bassuk SS, Toth PP: C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep, 2003; 5: 341-349
7. Clearfield MB: C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc, 2005; 105: 409-416
8. Fukuchi Y, Miura Y, Nabeno Y, Kato Y, Osawa T, Naito M: Immunohistochemical detection of oxidative stress biomarkers, dityrosine and N(epsilon)-(hexanoyl)lysine, and C-reactive protein in rabbit atherosclerotic lesions. J Atheroscler Thromb, 2008; 15: 185-192
9. Venugopal SK, Devaraj S, Jialal I: Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens, 2005; 14: 33-37
10. Katsuda S, Kaji T: Atherosclerosis and extracellular matrix. J Atheroscler Thromb, 2003; 10: 267-274 11) Pepys MB: CRP or not CRP ? That is the question. Arterioscler Thromb Vasc Biol, 2005; 25: 1091-1094
11. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB: C-reactive protein and coronary heart disease: a critical review. J Intern Med, 2008; 264: 295-314
12. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L: C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2004; 109: 647-655
13. Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB: Transgenic human CRP is not pro-atherogenic, proatherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis, 2008; 196: 248-255
14. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB: Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A, 2005; 102: 8309-8314
15. Taylor KE, Giddings JC, van den Berg CW: C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol, 2005; 25: 1225-1230
16. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, Sabin CA, Zychlinsky A, de Diego J: Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res, 2005; 97: e97-103
17. Pepys MB: C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat Clin Pract Nephrol, 2008; 4: 234-235
18. Dasu MR, Devaraj S, Du Clos TW, Jialal I: The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res, 2007; 48: 509-512
19. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000; 102: 2165-2168
20. Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation, 2003; 107: 398-404
21. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 2002; 106: 913-919
22. Kawasaki K, Smith RS Jr, Hsieh CM, Sun J, Chao J, Liao JK: Activation of the phosphatidylinositol 3-kinase/ protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol, 2003; 23: 5726-5737
23. Verma S, Anderson TJ: The ten most commonly asked questions about endothelial function in cardiology. Cardiol Rev, 2001; 9: 250-252
24. Tsutsui M: Neuronal nitric oxide synthase as a novel antiatherogenic factor. J Atheroscler Thromb, 2004; 11: 41-48
25. Schwartz R, Osborne-Lawrence S, Hahner L, Gibson LL, Gormley AK, Vongpatanasin W, Zhu W, Word RA, Seetharam D, Black S, Samols D, Mineo C, Shaul PW: C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res, 2007; 100: 1452-1459
26. Singh SK, Suresh MV, Voleti B, Agrawal A: The connection between C-reactive protein and atherosclerosis. Ann Med, 2008; 40: 110-120
27. Miura S, Matsuo Y, Saku K: Jun N-terminal kinase inhibitor blocks angiogenesis by blocking VEGF secretion and an MMP pathway. J Atheroscler Thromb, 2008; 15: 69-74
28. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989; 246: 1306-1309
29. Matsumoto T, Mugishima H: Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J Atheroscler Thromb, 2006; 13: 130-135
30. Knight EL, Warner AJ, Maxwell A, Prigent SA: Chimeric VEGFRs are activated by a small-molecule dimerizer and mediate downstream signalling cascades in endothelial cells. Oncogene, 2000; 19: 5398-5405
31. Zhong Y, Li SH, Liu SM, Szmitko PE, He XQ, Fedak PW, Verma S: C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension, 2006; 48: 504-511
32. Mineo C, Gormley AK, Yuhanna IS, Osborne-Lawrence S, Gibson LL, Hahner L, Shohet RV, Black S, Salmon JE, Samols D, Karp DR, Thomas GD, Shaul PW: FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res, 2005; 97: 1124-1131
33. Franke RP, Gräfe M, Schnittler H, Seiffge D, Mittermayer C, Drenckhahn D: Induction of human vascular endothelial stress fibres by fluid shear stress. Nature, 1984; 307: 648-649
34. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, Law RE: PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol, 1999; 33: 798-806
35. Bello G, Cailotto F, Hanriot D, Kolopp-Sarda MN, Latger-Cannard V, Hess K, Zannad F, Longrois D, Ropars A: C-reactive protein (CRP) increases VEGF-A expression in monocytic cells via a PI3-kinase and ERK 1/2 signaling dependent pathway. Atherosclerosis, 2008; 200: 286-293
36. Yamada KM, Araki M: Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci, 2001; 114: 2375-2382
37. Huang J, Kontos CD: PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem, 2002; 277: 10760-10766
38. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT: Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis, 2008; 199: 3-11
39. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J: C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol, 2000; 20: 2094-2099
40. Ridker PM, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation, 2004; 109: 1955-1959
41. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ JUPITER Study Group: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med, 2008; 359: 2195-2207
42. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation, 2004; 109: 2058-2067
43. Homma Y: Predictors of atherosclerosis. J Atheroscler Thromb, 2004; 11: 265-270
44. Tanigaki K, Mineo C, Yuhanna IS, Chambliss KL, Quon MJ, Bonvini E, Shaul PW: C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1. Circ Res, 2009; 104: 1275-1282
45. Turu MM, Slevin M, Matou S, West D, Rodríguez C, Luque A, Grau-Olivares M, Badimon L, Martinez-Gonzalez J, Krupinski J: C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression. BMC Cell Biol, 2008; 9: 47
46. Dimmeler S, Dernbach E, Zeiher AM: Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett, 2000; 477: 258-262
47. Morales-Ruiz M, Fulton D, Sowa G, Languino LR, Fujio Y, Walsh K, Sessa WC: Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res, 2000; 86: 892-896
48. Papapetropoulos A, García-Cardeña G, Madri JA, Sessa WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest, 1997; 100: 3131-3139
49. Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, Law RE: Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol, 2000; 401: 259-270
50. Tanaka K, Abe M, Sato Y: Roles of extracellular signalregulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn J Cancer Res, 1999; 90: 647-654
51. Goetze S, Kintscher U, Kim S, Meehan WP, Kaneshiro K, Collins AR, Fleck E, Hsueh WA, Law RE: Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration. J Cardiovasc Pharmacol, 2001; 38: 909-921